List of SBIR/STTR awards granted to Biotherapeutics Inc.
Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in August, 2021 for $361,510.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43HL160260-01 | Phase I | 361,510 | August 1, 2021 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in July, 2020 for $230,729.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43CA254616-01 | Phase I | 230,729 | July 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in January, 2021 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI156952-01 | Phase I | 300,000 | January 1, 2021 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in May, 2020 for $231,195.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI152584-01 | Phase I | 231,195 | May 1, 2020 | |||||||
A SBIR Phase II contract was awarded to Biotherapeutics Inc. in May, 2020 for $473,565.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44DK121561-02 | Phase II | 473,565 | May 12, 2020 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in April, 2019 for $233,239.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43DK121561-01 | Phase I | 233,239 | April 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in July, 2019 for $299,984.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI145361-01A1 | Phase I | 299,984 | July 1, 2019 | |||||||
A SBIR Phase II contract was awarded to Biotherapeutics Inc. in July, 2020 for $933,303.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44DK120338-02 | Phase II | 933,303 | July 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in September, 2020 for $295,453.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AT010991-01 | Phase I | 295,453 | September 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in April, 2019 for $281,612.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44DK120338-01A1 | Phase I | 281,612 | April 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in June, 2021 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI165190-01 | Phase I | 300,000 | June 11, 2021 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in August, 2018 for $299,576.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI134163-01A1 | Phase I | 299,576 | August 21, 2018 | |||||||
A SBIR Phase II contract was awarded to Biotherapeutics Inc. in July, 2022 for $563,659.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AI156952-02 | Phase II | 563,659 | July 1, 2022 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in September, 2016 for $250,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK109836-01A1 | Phase I | 250,000 | September 1, 2016 | |||||||
A STTR Phase I contract was awarded to Biotherapeutics Inc. for $188,333.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41DK099027-01A1 | Phase I | 188,333 | ||||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. for $148,288.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK097940-01A1 | Phase I | 148,288 | ||||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in April, 2023 for $356,068.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43DK135158-01A1 | Phase I | 356,068 | April 15, 2023 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in September, 2023 for $295,924.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AR082207-01A1 | Phase I | 295,924 | September 7, 2023 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in September, 2023 for $295,294.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AR083730-01 | Phase I | 295,294 | September 20, 2023 | |||||||
A SBIR Phase I contract was awarded to Biotherapeutics Inc. in September, 2023 for $295,924.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AR082756-01 | Phase I | 295,924 | September 5, 2023 |
